Investment report on Radient Pharmaceuticals from StockPreacher.com

StockPreacher.com announces an investment report featuring Radient Pharmaceuticals Corp. (AMEX:RPC). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: http://www.stockpreacher.com/n/RPC

Get our alerts BEFORE the rest of the market. Follow us on Twitter: https://twitter.com/StockPreacher

Radient Pharmaceuticals Corp. (RPC) is a vertically integrated specialty pharmaceutical company with three distinct business divisions that include in-vitro diagnostics, China-based pharmaceutical manufacturing and distribution and cancer therapeutics. These business units focus on the development, manufacturing, distribution and sales of medical diagnostic products, generic pharmaceuticals, nutritional supplements and cosmetics in the United States, China, Korea, Taiwan and other markets. Until recently, the Company was focused on the production and distribution of pharmaceutical products through the Company's subsidiaries located in China. The Company has recently refocused core business strategy and market focus to the international commercialization of its proprietary diagnostic tumor-marker test kit Onko-Sure™ (formally DR-70®) and Elleuxe brand of skin care products.

Message Board Search for RPC: http://www.boardcentral.com/boards/RPC

In the report, the analyst notes:

"RPC recently said its monoclonal antibody test it began working on 20 years ago, and the U.S. Food and Drug Administration (FDA) and many other international agencies have approved, may change how people screen for early cancer detection...Following the report, shares of RPC surged 86% to close at $0.70 in Thursday's trading, while volume topped 20 million shares.

"On April 7, the Company announced it entered into an exclusive five-year collaboration agreement with Jaiva Technologies, which supports the Company's expansion and commercialization strategy for its cancer products that also include the Onko-Sure™ in-vitro diagnostic cancer test. Under the terms of the agreement, Jaiva Technologies will collaborate with clinical laboratories, hospitals and physicians in India to conduct clinical trials for RPC's Combination Immunogene Therapy (CIT) technology."